O-Benzyl-N-methyl-L-tyrosine | 917615-19-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: O-Benzyl-N-methyl-L-tyrosine
• 英文别名: (2S)-2-(methylamino)-3-(4-phenylmethoxyphenyl)propanoic acid
• CAS: 917615-19-1
• 化学式: C₁₇H₁₉NO₃
• 分子量: 285.34
• InChiKey: INBIGRAQOQWDEZ-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Alpha-aminoamide derivatives as melanocortin agonists
  申请人：——

  公开号：US20030232807A1

  公开（公告）日：2003-12-18

  Novel piperazine and homopiperazine derivatives are agonists of melanocortin receptor(s) and are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of the melanocortin receptors. The compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders such as obesity, diabetes, and sexual dysfunction.

  新型哌嗪和异哌嗪衍生物是黑色素皮质激素受体的激动剂，并可用于治疗、控制或预防对黑色素皮质激素受体激活敏感的疾病和紊乱。因此，本发明的化合物可用于治疗或预防肥胖、糖尿病和性功能障碍等疾病和紊乱。
• RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210094933A1

  公开（公告）日：2021-04-01

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受免疫蛋白配体家族FK506和雷帕霉素天然产物启发的大环化合物。生成包含FK506和雷帕霉素结合结构域的Rapafucin大环化合物库，应具有作为治疗疾病新药的潜力。
• LHRH-II PEPTIDE ANALOGS
  申请人：Linder Karen E.

  公开号：US20120045393A1

  公开（公告）日：2012-02-23

  The invention is directed to analogs of LHRH-II and, more generally, to analogs of the LHRH family in which modifications have been made that confer enhanced binding affinity for LHRH receptors and/or improved metabolic stability. The invention is further directed to methods of targeted therapy and targeted imaging in patients with sex-hormone-related cancers or other LHRH-mediated diseases.

  该发明涉及LHRH-II的类似物，更一般地，涉及LHRH家族的类似物，其中进行了改性以赋予LHRH受体更强的结合亲和力和/或改善代谢稳定性。该发明进一步涉及在患有性激素相关癌症或其他LHRH介导疾病的患者中进行有针对性的治疗和有针对性的成像的方法。
• Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
  申请人：ELI LILLY AND COMPANY

  公开号：EP0030845A2

  公开（公告）日：1981-06-24

  Compounds of the formula and pharmaceutically acceptable non-toxic acid addition salts thereof, in which Land D define the chirality; R1 is hydrogen or C1-C3 primary alkyl; R2 is C1-C4 primary or secondary alkyl, allyl, cyclopropylmethyl, C1-C2 hydroxyalkyl, or -(CH2)m-U-CH3 in which U is -S- or S-0 and mis 1 or 2; R3 is hydrogen, C1-C4 primary or secondary alkyl, cyclopropylmethyl, allyl or propargyl; and in which R, is hydrogen, acetyl, or acetoxymethyl and R5 is C1-C3 alkyl; are useful analgesic agents. These compounds are prepared by deblocking the correspondingly blocked compound of formula I with a deblocking agent.

  式化合物 及其药学上可接受的无毒酸加成盐，其中 Land D 定义了手性； R1 是氢或 C1-C3 伯烷基； R2 是 C1-C4 伯烷基或仲烷基、 烯丙基、环丙基甲基、C1-C2 羟基烷基或-(CH2)m-U-CH3，其中 U 是-S-或 S-0 且误为 1 或 2；R3 是氢、C1-C4 伯或仲烷基、环丙基甲基、烯丙基或丙炔基；以及 其中 R，是氢、乙酰基或乙酰氧甲基，R5 是 C1-C3 烷基；这些都是有用的镇痛剂。这些化合物的制备方法是用解嵌剂对相应的式 I 嵌段化合物进行解嵌。
• Acceleration of Mycobacterium growth
  申请人：ST GEORGE'S HOSPITAL MEDICAL SCHOOL

  公开号：US10633630B2

  公开（公告）日：2020-04-28

  The invention is in the field of growth of Mycobacteria. In particular, agents have been identified which enhance the growth of Mycobacterial species, which are naturally slow-growing. Such agents can therefore be used in the identification of Mycobacteria and in the diagnosis of Mycobacterial infections.

  本发明属于分枝杆菌生长领域。特别是，已经发现了能促进自然生长缓慢的分枝杆菌生长的制剂。因此，这些制剂可用于分枝杆菌的鉴定和分枝杆菌感染的诊断。